A study has demonstrated that the inherited risk of early-onset cancer is significantly higher among Latino and African American families for solid tumors, and Asian/Pacific Islander families for blood-based cancers, compared to non-Latino white families in California.
Cancer immunotherapy involving drugs that inhibit CTLA-4 also activates an unwanted response that may self-limit its efficacy in fighting tumors, according to a new study led by Francesco Marangoni.
A study led by Yale Cancer Center scientists revealed the combination of ATR and PARP inhibitor therapies can effectively target the enzyme isocitrate dehydrogenase-I/2 (IDH-1/2) in mutant cancer cells.
A study by researchers at Yale Cancer Center shows that combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
A study led by Yale Cancer Center researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.
The European Commission has approved the PD-1 inhibitor Libtayo (cemiplimab) for the first-line treatment of adults with non-small cell lung cancer whose tumor cells have ≥50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended granting Conditional Marketing Authorization for Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
The Committee for Medicinal Products for Human Use of the European Medicines Agency as recommended approval of Opdivo (nivolumab) for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.
The European Commission has approved Onureg (azacitidine tablets)as the first and only once-daily, frontline oral maintenance therapy in the EU for patients with a broad range of acute myeloid leukemia subtypes.
Alan Rabson and Ruth Kirschstein came to NIH together and became a graceful power couple. Kirschstein would become a key contributor to the development of a safe and effective polio vaccine and the first woman director of a major institute at the NIH.
